<DOC>
	<DOCNO>NCT02723240</DOCNO>
	<brief_summary>A two-part , phase I open label , dose escalation expansion study ass safety , pharmacokinetics clinical activity NUC-3373 , nucleotide analogue , participant advance solid tumour .</brief_summary>
	<brief_title>NUC-3373 Advanced Solid Tumours</brief_title>
	<detailed_description>This two-part , Phase I dose escalation study NUC-3373 single agent , administer weekly fortnightly I.V . infusion . In part participant undergo evaluation safety , PK , PD anti-tumour efficacy NUC-3373 • Participants may continue receive NUC-3373 disease progression unacceptable toxicity occurs . Part 1 : Establish RP2D ass safety tolerability single agent NUC-3373 administer I.V . infusion day 1 , 8 , 15 , 22 28-day cycle . Participants remain study receive treatment disease progression unacceptable toxicity occur . The RP2D determine dose escalation sequential participant receive increase dos NUC-3373 standard ' 3 + 3 ' cohort design . Part 2 : Establish RP2D ass safety tolerability single agent NUC-3373 administer fortnightly I.V . infusion day 1 15 28-day cycle . Participants remain study receive treatment disease progression unacceptable toxicity occur . The RP2D determine dose escalation sequential participant receive increase dos NUC-3373 standard ' 3 + 3 ' cohort design . Finally , assess preliminary efficacy signal characterise safety profile , expansion cohort 20 additional participant per cohort receive RP2D NUC-3373 determine Part 1 Part 2 study . Participants remain study receive treatment disease progression unacceptable toxicity occur .</detailed_description>
	<criteria>1 . Provision sign write informed consent . 2 . Diagnosis : Histologically confirm diagnosis solid tumour , amenable standard chemotherapy , refractory standard chemotherapy standard chemotherapy exist . 3 . Age ≥ 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 5 . Life expectancy ≥ 12 week . 6 . Participants must measurable disease per RECIST criterion and/or evaluable disease ( evaluable : cytologically radiologically detectable disease ascites , peritoneal deposit , lesion fulfil RECIST criterion measurable disease ) . 7 . Adequate bone marrow function define : WBC ≥ 3 x109/L , ANC ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L , haemoglobin ≥ 9g/dL . 8 . Adequate liver function , determine : Serum total bilirubin ≤1.5 x ULN , AST ALT ≤ 2.5 x ULN . 9 . Adequate renal function define serum creatinine within ≤ 1.5 x ULN upper limit normal calculated clearance ≥50 ml/min/1.73 m2 . If use creatinine clearance , actual body weight used calculate creatinine clearance ( use CockcroftGault formula ) . For subject Body Mass Index ( BMI ) &gt; 30 kg/m2 , lean body weight use instead 10 . Left Ventricular Ejection Fraction ( LVEF ) ≥50 % echocardiogram 11 . Ability comply protocol requirement . 12 . Female participant childbearing potential must negative serum pregnancy test screen negative urine pregnancy test prior first schedule IMP administration Cycle 1 Day 1. . 1 . History allergic reaction attribute previous 5FU capecitabine treatment . 2 . History allergic reaction component Companion Infusion Solutions supply NUC3373 . 3 . Symptomatic CNS leptomeningeal metastasis . 4 . Participants history myocardial infarction within last 5 year significant cardiac arrhythmia require medication pacemaker . 5 . Prior chemotherapy , radiotherapy ( short cycle palliative radiotherapy bone pain ) , immunotherapy anticancer agent within 28 day first administration IMP . For nitrosoureas mitomycin C within 6 week first administration IMP . For hormone biological therapy within 14 day first administration IMP . 6 . Prior toxicity chemotherapy radiotherapy regress Grade ≤ 1 severity ( NCICTCAE version 4.0 ) apart renal function ( provide inclusion criterion 9 met ) , neuropathy alopecia . 7 . Another active cancer exclude basal cell carcinoma intraepithelial neoplasia ( CIN/cervical situ melanoma situ ) . 8 . Participants uncontrolled concomitant illness , active infection require i.v . antibiotic , uncontrolled infection , fever &gt; 38.5°C day schedule dosing . 9 . Participants serious illness , medical condition , medical history , include laboratory result , , CI delegate opinion would likely interfere participant 's participation study , interpretation result . 10 . Known HIV know active Hepatitis B C. 11 . Any condition ( e.g . know suspected poor compliance , psychological instability , geographical location , etc . ) , judgment CI delegate may affect participant 's ability sign inform consent undergo study procedure . 12 . All men woman reproductive potential , unless use least two contraceptive precaution , one must list , must condom*1 abstain sexual intercourse , six month treatment end : Combined ( oestrogen progesterone contain ) hormonal contraception associate inhibition ovulation : either oral , intravaginal transdermal . Progesteroneonly hormonal contraception associate inhibition ovulation : either oral , injectable implantable . Intrauterine device ( IUD ) Intrauterine hormonereleasing system ( IUS ) Bilateral tubal occlusion Vasectomised partner*2 Sexual abstinence*3 13 . Participants currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NUC-3373</keyword>
	<keyword>Dose escalation</keyword>
	<keyword>Nucleotide Analogue</keyword>
</DOC>